Is Evolus a good investment?
may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of EOLS, demonstrate its potential to underperform the market.
Is EOLS a good stock to buy?
The 7 analysts offering 12-month price forecasts for Evolus Inc have a median target of 15.00, with a high estimate of 20.00 and a low estimate of 10.00. The median estimate represents a +24.58% increase from the last price of 12.04.
What is Evolus company?
Who makes Jeuveau?
What's better Botox or Xeomin?
Where is Evolus located?
Is Evolus a buy right now?
6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last twelve months. There are currently 1...
How has Evolus' stock been impacted by Coronavirus?
Evolus' stock was trading at $5.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). S...
When is Evolus' next earnings date?
Evolus is scheduled to release its next quarterly earnings announcement on Wednesday, May 11th 2022. View our earnings forecast for Evolus .
How were Evolus' earnings last quarter?
Evolus, Inc. (NASDAQ:EOLS) posted its earnings results on Thursday, March, 3rd. The company reported ($0.22) earnings per share (EPS) for the quart...
What guidance has Evolus issued on next quarter's earnings?
Evolus issued an update on its FY 2022 earnings guidance on Thursday, March, 17th. The company provided EPS guidance of for the period. The company...
What price target have analysts set for EOLS?
6 brokers have issued 1-year price targets for Evolus' shares. Their forecasts range from $7.00 to $20.00. On average, they anticipate Evolus' stoc...
Who are Evolus' key executives?
Evolus' management team includes the following people: David Moatazedi , President, Chief Executive Officer & Director ( LinkedIn Profile ) Laur...
What is David Moatazedi's approval rating as Evolus' CEO?
1 employees have rated Evolus CEO David Moatazedi on Glassdoor.com . David Moatazedi has an approval rating of 100% among Evolus' employees. This...
Who are some of Evolus' key competitors?
Some companies that are related to Evolus include Mawson Infrastructure Group (WIZP) , Zentalis Pharmaceuticals (ZNTL) , Schrödinger (SDGR) , E...
Is Evolus a buy right now?
8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock.
What stocks does MarketBeat like better than Evolus?
Wall Street analysts have given Evolus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Evolus wasn't one of them.
When is Evolus' next earnings date?
Evolus is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.#N#View our earnings forecast for Evolus.
How were Evolus' earnings last quarter?
Evolus, Inc. (NASDAQ:EOLS) released its quarterly earnings results on Wednesday, August, 4th. The company reported ($0.31) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.01. The company earned $26.10 million during the quarter, compared to the consensus estimate of $25.51 million.
How has Evolus' stock been impacted by Coronavirus (COVID-19)?
Evolus' stock was trading at $5.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EOLS stock has increased by 74.8% and is now trading at $10.33.#N#View which stocks have been most impacted by COVID-19.
What price target have analysts set for EOLS?
8 Wall Street analysts have issued twelve-month target prices for Evolus' shares. Their forecasts range from $7.00 to $25.00. On average, they anticipate Evolus' stock price to reach $16.38 in the next twelve months.
What is David Moatazedi's approval rating as Evolus' CEO?
1 employees have rated Evolus CEO David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among Evolus' employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
Evolus Media Sentiment
Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.
Media Coverage
We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.
Evolus (NASDAQ EOLS) News Headlines Today
Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm.
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision.
When Will Evolus, Inc. (NASDAQ:EOLS) Become Profitable?
Evolus, Inc. ( NASDAQ:EOLS ) is possibly approaching a major achievement in its business, so we would like to shine...
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates
Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -12.50% and 2.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know
Evolus, Inc. (EOLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Evolus Disrupt the Botox Market?
The facial injections industry is estimated to be valued at $13.4 billion and is expected to grow at an 8.8% compound annual growth rate until 2028. The leader in facial injections is the well-known Botox product, which was invented by Allergan, a company now owned by biotechnology giant AbbVie (NYSE: ABBV). Does Evolus have what it takes?
Repeat Doses Of Evolus' Frown Lines Treatment Are Safe, With Decreasing Rates Of Adverse Events
Evolus Inc (NASDAQ: EOLS) has announced two newly published peer review studies in Aesthetic Surgery Journal that provide supportive evidence of the safety and efficacy of repeat doses of prabotulinumtoxinA (Jeuveau) to decrease the appearance of glabellar lines (also known as frown lines between the eyes).
Aurora Cannabis (ACB) to Post Q3 Earnings: What's in Store?
Aurora Cannabis' (ACB) sturdy consumer cannabis sales are likely to have benefited its performance in the fiscal third quarter.
EOLS Target Price
EOLS price target in 14 days: 11.243 USD* upside and 10.001 USD* downside. (Highest and lowest possible predicted price in a 14 day period)
Evolus Inc ( EOLS ) Stock Market info
Recommendations: Buy or sell Evolus stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Evolus share forecasts, stock quote and buy / sell signals below. According to present data Evolus's EOLS shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).
Also on walletinvestor.com
Villahome — Sunrise resources c.s. Site valued at $3 billion gross. Check this out.
Is Jeuveau cheaper than Botox?
What makes Jeuveau compelling for doctors is that it is already as cheap as Botox, but has earned better results in customer satisfaction surveys. In a recent survey comparing Jeuveau to Botox, participants thought that Evolus's product was better at reducing wrinkles in blind trials.
What is a Jeuveau?
What is Jeuveau? Jeuveau is an injectable serum containing the botulinum toxin type A compound, the same active ingredient that's in Botox and other facial injection products. In 2019, the U.S. Food and Drug Administration (FDA) approved the use of Jeuveau for glabellar lines (wrinkles in between the eyebrows).
How much is facial injections worth?
The facial injections industry is estimated to be valued at $13.4 billion and is expected to grow at an 8.8% compound annual growth rate until 2028. The leader in facial injections is the well-known Botox product, which was invented by Allergan, a company now owned by biotechnology giant AbbVie ( NYSE:ABBV). The product wins over $1 billion in sales a year just in cosmetics (non-medical injections). However, a product from performance beauty company Evolus ( NASDAQ:EOLS) called Jeuveau is looking to shake up the facial injections market. Does Evolus have what it takes?
Who makes Botox injections?
The leader in facial injections is the well-known Botox product, which was invented by Allergan, a company now owned by biotechnology giant AbbVie ( NYSE:ABBV). The product wins over $1 billion in sales a year just in cosmetics (non-medical injections). However, a product from performance beauty company Evolus ...
Is Evolus a CRL?
Evolus announced today that its lead compound, DWP-450, received a CRL from the FDA, which is a nice way of saying that it was rejected. DWP-450 is a hopeful treatment for frown lines in adult patients and would be a direct competitor to the Allergan 's ( NYSE:AGN) blockbuster drug botox should it eventually win approval.
Is a CRL good news?
While a CRL is never good news, the fact that it does not require the company to perform any additional clinical tests is certainly a positive. That suggests that this rejection should be viewed as a delay in the drug's approval date and not a reason for investors to abandon hope.
Where is DWP 450 manufactured?
Managment was also eager to point out in the press release that the company's manufacturing facility in South Korea that will produce DWP-450 was issued a favorable Establishment Inspection Report (EIR) by the FDA.